NASDAQ : RLMD
Relmada Therapeutics, Inc. — Financial statements
Healthcare · Biotechnology · United States
Last price 3.58 USD (Oct 30, 2026, 4:00 PM EDT) · Market cap 381.88M
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Financial statements
Income statement
Fiscal year January - December; amounts in USD.
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | |
|---|---|---|---|---|---|---|
| Selling, General & Admin | 36.54M | 32.22M | 37.72M | 48.89M | 47.93M | 35.08M |
| Research & Development | 25.69M | 23.98M | 46.18M | 54.81M | 113.32M | 90.62M |
| Operating Expenses | 62.23M | 56.20M | 83.89M | 103.70M | 161.25M | 125.70M |
| Operating Income | -62.23M | -56.20M | -83.89M | -103.70M | -161.25M | -125.70M |
| Interest & Investment Income | 3.90M | 1.40M | 3.53M | 5.15M | 2.66M | 1.20M |
| EBT Excluding Unusual Items | -58.34M | -54.80M | -80.36M | -98.55M | -158.59M | -124.50M |
| Merger & Restructuring Charges | -2.90M | -2.90M | ||||
| Gain (Loss) on Sale of Investments | -687.56K | 319.05K | 381.66K | -241.16K | -4.81M | -1.25M |
| Other Unusual Items | 6.35M | |||||
| Pretax Income | -61.93M | -57.39M | -79.98M | -98.79M | -157.04M | -125.75M |
| Net Income | -61.93M | -57.39M | -79.98M | -98.79M | -157.04M | -125.75M |
| Net Income to Common | -61.93M | -57.39M | -79.98M | -98.79M | -157.04M | -125.75M |
| Shares Outstanding (Basic) | 73.24M | 39.48M | 30.16M | 30.10M | 29.63M | 17.55M |
| Shares Outstanding (Diluted) | 73.24M | 39.48M | 30.16M | 30.10M | 29.63M | 17.55M |
| EPS (Basic) | -0.85 | -1.45 | -2.65 | -3.28 | -5.30 | -7.16 |
| EPS (Diluted) | -0.85 | -1.45 | -2.65 | -3.28 | -5.30 | -7.16 |
| Free Cash Flow | -45.99M | -45.79M | -51.76M | -51.66M | -103.80M | -91.87M |
| Free Cash Flow Per Share | -0.63 | -1.16 | -1.72 | -1.72 | -3.50 | -5.23 |
| EBITDA | -161.25M | -125.70M | ||||
| D&A For EBITDA | 1.26K | 1.26K | ||||
| EBIT | -62.23M | -56.20M | -83.89M | -103.70M | -161.25M | -125.70M |
Balance sheet
Fiscal year January - December; amounts in USD.
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | |
|---|---|---|---|---|---|---|
| Cash & Equivalents | 11.33M | 3.50M | 3.86M | 4.09M | 5.40M | 44.44M |
| Short-Term Investments | 206.40M | 89.51M | 41.05M | 92.23M | 142.93M | 167.47M |
| Cash & Short-Term Investments | 217.73M | 93.01M | 44.91M | 96.32M | 148.32M | 211.91M |
| Other Receivables | 10.91K | 512.43K | 86.38K | |||
| Receivables | 10.91K | 512.43K | 86.38K | |||
| Prepaid Expenses | 1.30M | 977.72K | 886.46K | 1.19M | 4.04M | 11.30M |
| Total Current Assets | 219.04M | 93.98M | 45.80M | 97.51M | 152.87M | 223.30M |
| Other Long-Term Assets | 19.50K | 19.50K | 21.98K | 43.12K | 34.88K | 28.29K |
| Total Assets | 219.06M | 94.00M | 45.82M | 97.55M | 152.91M | 223.33M |
| Accounts Payable | 2.41M | 1.57M | 4.13M | 3.51M | 5.26M | 11.19M |
| Accrued Expenses | 5.01M | 4.86M | 6.16M | 8.69M | 7.21M | 3.87M |
| Total Current Liabilities | 7.42M | 6.43M | 10.29M | 12.19M | 12.47M | 15.06M |
| Other Long-Term Liabilities | 5.08M | 1.06M | 4.47K | |||
| Total Liabilities | 12.50M | 7.49M | 10.30M | 12.19M | 12.47M | 15.06M |
| Common Stock | 106.67K | 73.33K | 30.17K | 30.10K | 30.10K | 27.74K |
| Additional Paid-In Capital | 936.68M | 784.71M | 676.37M | 646.23M | 602.52M | 513.30M |
| Retained Earnings | -730.23M | -698.27M | -640.88M | -560.90M | -462.11M | -305.07M |
| Shareholders' Equity | 206.56M | 86.51M | 35.52M | 85.36M | 140.44M | 208.26M |
| Total Liabilities & Equity | 219.06M | 94.00M | 45.82M | 97.55M | 152.91M | 223.33M |
| Net Cash (Debt) | 217.73M | 93.01M | 44.91M | 96.32M | 148.32M | 211.91M |
| Net Cash Per Share | 2.97 | 2.36 | 1.49 | 3.20 | 5.01 | 12.07 |
| Filing Date Shares Outstanding | 106.67M | 104.89M | 33.19M | 30.17M | 30.10M | 29.37M |
| Total Common Shares Outstanding | 106.67M | 73.33M | 30.10M | 30.10M | 30.10M | 27.74M |
| Working Capital | 211.62M | 87.55M | 35.50M | 85.31M | 140.40M | 208.24M |
| Book Value Per Share | 1.94 | 1.18 | 1.18 | 2.84 | 4.67 | 7.51 |
| Tangible Book Value | 206.56M | 86.51M | 35.52M | 85.36M | 140.44M | 208.26M |
| Tangible Book Value Per Share | 1.94 | 1.18 | 1.18 | 2.84 | 4.67 | 7.51 |
Cash flow statement
Fiscal year January - December; amounts in USD.
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | |
|---|---|---|---|---|---|---|
| Net Income | -61.93M | -57.39M | -79.98M | -98.79M | -157.04M | -125.75M |
| Depreciation & Amortization | 1.26K | |||||
| Loss (Gain) From Sale of Investments | 687.56K | -319.05K | -381.66K | 241.16K | 4.81M | 1.25M |
| Stock-Based Compensation | 14.70M | 15.87M | 30.19M | 43.81M | 44.19M | 40.49M |
| Other Operating Activities | -905.23K | -6.35M | ||||
| Change in Accounts Receivable | 512.43K | -512.43K | ||||
| Change in Accounts Payable | 1.05M | -2.56M | 624.55K | -1.76M | 421.04K | 2.85M |
| Change in Other Net Operating Assets | 407.55K | -1.39M | -2.21M | 4.32M | 10.68M | -10.71M |
| Operating Cash Flow | -45.99M | -45.79M | -51.76M | -51.66M | -103.80M | -91.87M |
| Investment in Securities | -187.82M | -48.14M | 51.56M | 50.45M | 19.73M | -54.12M |
| Investing Cash Flow | -187.82M | -48.14M | 51.56M | 50.45M | 19.73M | -54.12M |
| Issuance of Common Stock | 253.74M | 93.64M | 246.75K | 44.70M | 187.94M | |
| Other Financing Activities | -9.95M | -73.02K | -287.09K | -98.46K | 323.63K | |
| Financing Cash Flow | 243.79M | 93.56M | -40.34K | -98.46K | 45.02M | 187.94M |
| Net Cash Flow | 9.98M | -360.49K | -234.54K | -1.30M | -39.05M | 41.95M |
| Free Cash Flow | -45.99M | -45.79M | -51.76M | -51.66M | -103.80M | -91.87M |
| Free Cash Flow Per Share | -0.63 | -1.16 | -1.72 | -1.72 | -3.50 | -5.23 |
| Levered Free Cash Flow | -23.65M | -23.21M | -23.85M | -17.91M | -52.34M | -46.02M |
| Unlevered Free Cash Flow | -23.65M | -23.21M | -23.85M | -17.91M | -52.34M | -46.02M |
| Cash Income Tax Paid | 4.42K | 4.42K | ||||
| Change in Working Capital | 1.45M | -3.95M | -1.58M | 3.08M | 10.59M | -7.86M |
Ratios
Fiscal year January - December; amounts in USD.
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | |
|---|---|---|---|---|---|---|
| Market Capitalization | 381.88M | 354.20M | 15.69M | 124.61M | 105.05M | 624.67M |
| Enterprise Value | 164.15M | 340.31M | -38.43M | 18.34M | -79.11M | 536.58M |
| Last Close Price | 3.58 | 4.83 | 0.52 | 4.14 | 3.49 | 22.53 |
| PB Ratio | 1.85 | 4.09 | 0.44 | 1.46 | 0.75 | 3.00 |
| P/TBV Ratio | 1.85 | 4.09 | 0.44 | 1.46 | 0.75 | 3.00 |
| Net Debt / Equity Ratio | -1.05 | -1.07 | -1.26 | -1.13 | -1.06 | -1.02 |
| Net Debt / EBITDA Ratio | 0.92 | 1.69 | ||||
| Net Debt / FCF Ratio | 4.73 | 2.03 | 0.87 | 1.86 | 1.43 | 2.31 |
| Quick Ratio | 29.34 | 14.46 | 4.36 | 7.90 | 11.94 | 14.08 |
| Current Ratio | 29.52 | 14.62 | 4.45 | 8.00 | 12.26 | 14.83 |
| Return on Equity (ROE) | -55.66% | -94.05% | -132.33% | -87.51% | -90.07% | -80.14% |
| Return on Assets (ROA) | -32.39% | -50.24% | -73.14% | -51.76% | -53.57% | -46.01% |
| Return on Capital Employed (ROCE) | -29.40% | -64.20% | -236.10% | -121.50% | -114.80% | -60.40% |
| Earnings Yield | -23.62% | -16.20% | -509.73% | -79.28% | -149.50% | -20.13% |
| FCF Yield | -12.04% | -12.93% | -329.85% | -41.46% | -98.81% | -14.71% |
| Buyback Yield / Dilution | -136.32% | -30.89% | -0.21% | -1.59% | -68.80% | -12.56% |